MX2018001918A - Aplicación cuantitativa periorbital de farmacos oftalmologicos. - Google Patents

Aplicación cuantitativa periorbital de farmacos oftalmologicos.

Info

Publication number
MX2018001918A
MX2018001918A MX2018001918A MX2018001918A MX2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A
Authority
MX
Mexico
Prior art keywords
ophthalmology
peri
drugs
quantitative
orbital
Prior art date
Application number
MX2018001918A
Other languages
English (en)
Inventor
Woodward David
Wang Weizhen
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of MX2018001918A publication Critical patent/MX2018001918A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se dirige a métodos para disminuir la presión intraocular en un paciente que padece presión intraocular elevada o glaucoma y para tratar la enfermedad ocular administrando un fármaco a la piel periorbital del paciente.
MX2018001918A 2015-08-19 2016-08-17 Aplicación cuantitativa periorbital de farmacos oftalmologicos. MX2018001918A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/829,789 US9820954B2 (en) 2015-08-19 2015-08-19 Quantitative peri-orbital application of ophthalmology drugs
PCT/US2016/047230 WO2017031137A1 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Publications (1)

Publication Number Publication Date
MX2018001918A true MX2018001918A (es) 2018-11-09

Family

ID=58051248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001918A MX2018001918A (es) 2015-08-19 2016-08-17 Aplicación cuantitativa periorbital de farmacos oftalmologicos.

Country Status (9)

Country Link
US (1) US9820954B2 (es)
EP (1) EP3337474A4 (es)
JP (1) JP6924429B2 (es)
KR (1) KR102685479B1 (es)
CN (1) CN108135873A (es)
AU (1) AU2016308105B2 (es)
CA (1) CA2992483C (es)
MX (1) MX2018001918A (es)
WO (1) WO2017031137A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
KR20200037230A (ko) * 2017-06-30 2020-04-08 제니비젼 인크. 모발 성장용 제제
CA3206609A1 (en) * 2021-02-05 2022-08-11 Weizhen Wang Compositions and methods for periorbital administration of ep2 receptor agonists
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3990444A (en) 1972-11-22 1976-11-09 Vial S.A.R.L. Blood transfusion apparatus
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
DE3851152T2 (de) 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
CA2563365A1 (en) 2004-04-23 2005-11-03 Mystic Pharmaceuticals, Inc. Multiple unit dose drug delivery system
US7226435B2 (en) 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
EP1893216A4 (en) * 2005-06-08 2012-08-08 Targegen Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
EP2015733A2 (en) 2006-04-26 2009-01-21 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
US20090318422A1 (en) 2006-08-28 2009-12-24 Akiharu Isowaki Ophthalmic percutaneous absorption type preparation
US20080107644A1 (en) * 2006-10-31 2008-05-08 Alcon Manufacturing, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
DK2173407T3 (da) 2007-07-02 2020-04-27 Hoffmann La Roche Anordning til indgivelse af lægemiddel
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
MX2010005012A (es) 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
MX2010008226A (es) * 2008-02-05 2010-10-25 Asterand Uk Ltd Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
PL2493474T3 (pl) 2009-10-30 2020-03-31 Intratus, Inc. Sposoby i kompozycje do podtrzymywanego dostarczania leków
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
US20130085472A1 (en) 2010-03-09 2013-04-04 Toxcure, LLC Microneedle nasal delivery device
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
GB2482691B (en) 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
AR087814A1 (es) * 2011-09-16 2014-04-16 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
AU2012339695B2 (en) 2011-11-15 2017-10-05 Allergan, Inc. Sustained action formulation of cyclosporin Form 2
WO2014045300A2 (en) 2012-09-03 2014-03-27 Fdc Limited "topical drug delivery system"
CN203379477U (zh) 2012-12-14 2014-01-08 上海市第七人民医院 一种微针滚轮装置

Also Published As

Publication number Publication date
KR20180042348A (ko) 2018-04-25
US9820954B2 (en) 2017-11-21
JP6924429B2 (ja) 2021-08-25
AU2016308105B2 (en) 2021-05-27
AU2016308105A1 (en) 2018-02-15
CA2992483C (en) 2024-03-19
EP3337474A1 (en) 2018-06-27
EP3337474A4 (en) 2019-04-10
WO2017031137A1 (en) 2017-02-23
JP2018528169A (ja) 2018-09-27
CN108135873A (zh) 2018-06-08
KR102685479B1 (ko) 2024-07-15
US20170049734A1 (en) 2017-02-23
CA2992483A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
UY33481A (es) Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular
EA201790889A1 (ru) Офтальмологический раствор
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
EP3405159A4 (en) TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION
MY199237A (en) Methods of treating ocular conditions
SG11201408323RA (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
EP4245295A3 (en) Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
BR112012023749A2 (pt) método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
TN2016000259A1 (en) Salbutamol (albuterol) eye protective medicament.
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
Yu et al. Using spectral-domain optical coherence tomography imaging to identify the presence of retinal silicone oil emulsification after silicone oil tamponade.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
Pasyechnikova et al. Report on International Scientific Conference" Filatov Memorial Lecture-2016" dedicated to 140th Birth Anniversary of Academician VP Filatov
WO2019013518A3 (ko) 단풍나무 잎 추출물을 포함하는 안압 저하용 조성물
PH12017501796A1 (en) Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient
PL398967A1 (pl) Zastosowanie kwasu loganowego w terapii jaskry